April 21, 2021
I hope that you are safe and well. Coronavirus disease which is COVID-19, has affected all of our lives primarily since the end of 2019. We have faced experiences and a period that we had never come across before. Majorly, we have to wear masks, we should have social distance and we should have sterility in order to avoid it because this infectious disease spreads through droplets of saliva or discharge from the nose when an infected person coughs or sneezes, according to the definition of WHO.
Some of us still may not know about the virus itself. Well, they are a large family of viruses that cause illness ranging from the common cold to more serious diseases such as Severe Acute Respiratory Syndrome (SARS-CoV). The 2019 version of coronavirus; Covid-19 was not seen in humans before and it has caused viral pneumonia and has spread all over the world since December 2019.
Many pharmaceutical companies and scientists have been working on the solution. A lot of work and research have been done on the “Vaccines” as well as the on the pharmaceutical products for the treatment that could be the solution for the disease.
I’m honored to say that, for the second time I have shared an article (about Covid-19) with IPI – International Pharmaceutical Industry Journal, which is a very reputable and important journal, based in UK . So, my article “Comparison of Regulatory Process of Covid-19 Vaccines Between Emerging markets, EU” has been publishedin IPI Journal Volume 13 issue 1on pages 28 to 31. Please go to the link :
I’m sending my special thanks to Martin Wright and Virginia Toteva in IPI .
Stay safe and take care !